BDTX Reports 60% ORR, 15.2 Months mPFS, 86% CNS ORR for Silevertinib in Frontline NSCLC with EGFR Non-Classical Mutations
Black Diamond Therapeutics, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $2.26
-36% in 1d after detection
Post-detection moves
1h
—
1d
-36%
3d
-35%
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS